“It's a really simple tool to predict your out-of-pocket costs,” says Benjamin Pockros, MD, MBA, of Medicare Plan Finder.
In this interview, Benjamin Pockros, MD, MBA, discusses the presentation “Out-Of-Pocket Costs for Prostate Cancer Medications Substantially Vary by Part D Plan: An Online Tool Could Save Patients Thousands of Dollars,” which he gave at the 2022 Society of Urologic Oncology Annual Meeting in San Diego, California. Pockros is a urology resident at the University of Michigan, Ann Arbor.
KIM-1 emerges as biomarker for MRD, atezolizumab benefit in renal cell carcinoma
June 3rd 2024Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.